Skip to main content

Table 2 Demographic and clinical data of patients with NMDAR, CASPR2 or GAD65 antibodies and of their controls

From: The significance of anti-neuronal antibodies for acute psychiatric disorders: a retrospective case–controlled study

  NMDAR CASPR2 GAD65
Cases (n = 21) Controls (n = 42) Cases (n = 14) Controls (n = 28) Cases (n = 9) Controls (n = 18)
Age, mean (SD) 48.6 (16.3) 46.7 (14.2) 45.0 (16.1) 43.4 (14.7) 47.1 (14.0) 45.8 (11.8)
Sex, men (%) 62 62 71 71 56 56
Education, n (%)       
 ≤ 9 years 9 (43) 20 (48) 6 (43) 9 (32) 4 (44) 7 (39)
 10–12 years 7 (33) 14 (33) 2 (14) 13 (46) 4 (44) 9 (50)
 > 12 years 5 (24) 8 (19) 6 (43) 6 (21) 1 (11) 2 (11)
Psychiatric diagnosis, n (%)       
 Substance use disorder (F10–19) 4 (19) 7 (17) 3 (21) 6 (21) 2 (22) 3 (17)
 Psychotic disorder (F20–29) 1 (6) 6 (14) 2 (14) 6 (21) 1 (11) 1 (6)
 Affective disorder (F30–39) 8 (38) 20 (48) 5 (36) 12 (43) 3 (33) 9 (50)
 Other psychiatric disordersa 8 (38) 9 (21) 4 (29) 4 (14) 3 (33) 5 (28)
Psychopharmacological med. at admission, n (%)       
 Antipsychotic med. 6 (29) 13 (31) 5 (36) 10 (36) 3 (33) 5 (28)
 Antipsychotic dose, mean (SD)b 482 (422) 458 (302) 241 (185) 324 (170) 1071 (124) 469 (276)*
 Antidepressive med. 8 (38) 9 (21) 4 (29) 8 (29) 3 (33) 6 (33)
 Mood stabilizing med. 3 (14) 10 (24) 2 (14) 4 (14) 2 (22) 3 (17)
 No psychopharmacological med. 10 (48) 18 (43) 5 (36) 12 (43) 4 (44) 8 (44)
Psychopharmacological med. at discharge, n (%)       
 Antipsychotic med. 9 (43) 26 (62) 6 (43) 18 (64) 5 (56) 11 (61)
 Antipsychotic dose, mean (SD)b 418 (449) 408 (331) 222 (203) 342 (226) 784 (403) 331 (254)*
 Antidepressive med. 9 (43) 7 (17)* 4 (29) 7 (25) 2 (22) 6 (33)
 Mood stabilizing med. 6 (29) 15 (36) 5 (36) 6 (21) 2 (22) 5 (28)
 No psychopharmacological med. 5 (24) 10 (24) 3 (21) 5 (18) 2 (22) 5 (28)
Number of days admitted, mean (SD) 9.5 (11.4) 9.9 (9.1) 9.5 (6.1) 10.1 (11.6) 9.6 (9.3) 9.1 (8.3)
Alcohol or substance use days/weeks prior to admission, n (%) 16 (76) 21 (50)* 10 (71) 18 (64) 7 (78) 10 (56)
History of seizuresc 1 (6) 9 (25) 4 (40) 3 (13) 2 (22) 3 (18)
  1. CASPR2 contactin-associated protein 2, eq equivalents, GAD65 glutamic acid decarboxylase 65, med medication, NMDAR N-methyl-d-aspartate receptor, SD standard deviation
  2. *p < 0.05
  3. a3 patients with organic mental disorder (F00–09), 13 patients with anxiety disorders (F40–49), 7 patients with personality disorders (F60–69), 1 patient with mental retardation (F70–79), 1 patient with ADHD (F90–98) and 5 patients without specific psychiatric disorder (Z00–99); bchlorpromazine equivalents; cself-reported at admission (missing data; NMDAR, 3 cases and 6 controls; CASPR2, 4 cases and 5 controls; GAD, 1 control